CYP19A1 and fatty liver disease: In participants with hepatic steatosis, 22 TEAEs were reported in 5 out of 6 (83.3%) participants receiving ARO-ANG3 compared to 8 TEAEs reported in all 3 (100%) participants receiving placebo (Extended Data Table 3).